Investor Overview

We are a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules.

In March 2012, we launched Subsys® , our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in adult opioid-tolerant patients, through our cost-efficient commercial organization of approximately 250 sales professionals.

Since late 2014, Subsys® has been the most prescribed transmucosal immediate-release fentanyl, or TIRF, product with 48% market share on a prescription basis, according to IMS.

In December 2011, we launched Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS, through our exclusive distributor, a leading generic pharmaceutical company.

Our lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved. We intend to market Dronabinol Oral Solution and any other future supportive care products, if approved, through our commercial organization.

Please see full prescribing information for Subsys® including the boxed warning.

 

Recent News

Nov 02 2017
INSYS Therapeutics Reports Third Quarter 2017 Results
Official Launch of SYNDROS® and Filing NDA for Buprenorphine Sublingual Spray Drive Progress on Strategic Initiatives PHOENIX, Nov. 02, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), today reported financial result... 
Oct 30 2017
INSYS Therapeutics Provides Update on NASDAQ Trading Hold
PHOENIX, Oct. 30, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), subsequent to the trading hold placed on its stock on Thursday after market close, received a series of questions on Friday from NASDAQ. Those ques... 
Oct 29 2017
INSYS Therapeutics to Record a Minimum Liability for Department of Justice Settlement in Q3 2017
PHOENIX, Oct. 29, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), today made the following statement about the Department of Justice (DOJ) investigation. In connection with our cooperation with the DOJ, we have be... 
see all news

Receive Email Alerts

Sign Up Now

Upcoming Events

There are currently no events scheduled.

see all events